ALLOGENE THERAPEUTICS INC

NASDAQ: ALLO (Allogene Therapeutics, Inc.)

Kemas kini terakhir: 05 Jul, 2:52PM

1.19

-0.01 (-0.83%)

Penutupan Terdahulu 1.20
Buka 1.20
Jumlah Dagangan 1,384,912
Purata Dagangan (3B) 3,098,719
Modal Pasaran 260,289,920
Harga / Jualan (P/S) 7.78
Harga / Buku (P/B) 0.700
Julat 52 Minggu
0.860 (-27%) — 3.78 (217%)
Tarikh Pendapatan 6 Aug 2025
EPS Cair (TTM) -1.22
Pertumbuhan Hasil Suku Tahunan (YOY) -100.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 23.07%
Nisbah Semasa (MRQ) 9.71
Aliran Tunai Operasi (OCF TTM) -197.33 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -96.65 M
Pulangan Atas Aset (ROA TTM) -28.92%
Pulangan Atas Ekuiti (ROE TTM) -59.60%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok Allogene Therapeutics, Inc. Bercampur Menurun

AISkor Stockmoo

1.5
Konsensus Penganalisis 4.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 3.5
Osilator Teknikal -2.0
Purata 1.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALLO 260 M - - 0.700
HRMY 2 B - 13.72 2.78
CGON 2 B - - 2.70
CVAC 1 B - 5.80 1.62
SANA 1 B - - 4.55
GYRE 654 M - 360.50 10.13

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 17.74%
% Dimiliki oleh Institusi 80.54%
51.3551.3539.8039.8028.2528.2516.7016.705.155.15Harga Sasaran MedianQ4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
0.860 (-27%) — 3.78 (217%)
Julat Harga Sasaran
4.00 (236%) — 10.00 (740%)
Tinggi 10.00 (Truist Securities, 740.34%) Beli
10.00 (RBC Capital, 740.34%) Beli
Median 9.00 (656.30%)
Rendah 4.00 (Citigroup, 236.13%) Beli
Purata 8.17 (586.56%)
Jumlah 6 Beli
Harga Purata @ Panggilan 0.973
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Citigroup 15 May 2025 4.00 (236.13%) Beli 1.09
Baird 14 May 2025 9.00 (656.30%) Beli 0.950
Oppenheimer 14 May 2025 9.00 (656.30%) Beli 0.950
Piper Sandler 14 May 2025 7.00 (488.24%) Beli 0.950
RBC Capital 14 May 2025 10.00 (740.34%) Beli 0.950
Truist Securities 14 May 2025 10.00 (740.34%) Beli 0.950

Tiada data dalam julat masa ini.

1.351.351.271.271.191.191.111.111.031.03Jul 7Jul 7Jul 8Jul 8Jul 9Jul 9Jul 10Jul 10Jul 11Jul 11Jul 14Jul 14Jul 15Jul 15Jul 16Jul 16

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0200.0200.0150.0150.0100.0100.0050.0050.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda